secwatch / observer
ESPR Esperion Therapeutics, Inc.
CIK 0001434868 50 ready 8-Ks latest July 13, 2026, 9:10 AM ET RSS · JSON
Activity: QUIET 0 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (8)
Ready 8-Ks 50
Latest filing July 13, 2026, 9:10 AM ET
Top materiality 1.00
Event mix other_material ×16 · earnings ×15 · m_and_a ×8
Sentiment 26 pos · 3 neg · 21 neu
Latest earnings reported 2025-FY
Executive change recent →
SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for ESPR

Highest-materiality recent filing

Esperion acquired by Essence Parent for $3.16/share plus CVRs; merger closed July 13, 2026

July 13, 2026, 9:10 AM ET M&A materiality 1.00 neutral item 1.01item 1.02item 2.01item 2.03item 3.01item 3.03item 5.01item 5.03item 5.02item 9.01 ◈ executive_change ×8

Read filing →

Executive changes

Departed

Robert E. Hoffman

director
ESPR · Esperion Therapeutics, Inc.
Effective
2026-07-13
Filed
July 13, 2026, 9:10 AM ET
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
Departed

Sheldon L. Koenig

director
ESPR · Esperion Therapeutics, Inc.
Effective
2026-07-13
Filed
July 13, 2026, 9:10 AM ET
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
Departed

Seth H.Z. Fischer

director
ESPR · Esperion Therapeutics, Inc.
Effective
2026-07-13
Filed
July 13, 2026, 9:10 AM ET
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
Departed

Jay P. Shepard

director
ESPR · Esperion Therapeutics, Inc.
Effective
2026-07-13
Filed
July 13, 2026, 9:10 AM ET
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
Appointed

Ankit Pareek

director
ESPR · Esperion Therapeutics, Inc.
Effective
2026-07-13
Filed
July 13, 2026, 9:10 AM ET
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
Departed

J. Martin Carroll

director
ESPR · Esperion Therapeutics, Inc.
Effective
2026-07-13
Filed
July 13, 2026, 9:10 AM ET
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
Appointed

Justin Bateman

director
ESPR · Esperion Therapeutics, Inc.
Effective
2026-07-13
Filed
July 13, 2026, 9:10 AM ET
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
Departed

Craig Thompson

director
ESPR · Esperion Therapeutics, Inc.
Effective
2026-07-13
Filed
July 13, 2026, 9:10 AM ET
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
Departed

Eric Warren

Chief Commercial Officer
ESPR · Esperion Therapeutics, Inc.
Effective
2025-04-18
Filed
April 4, 2025, 7:59 PM ET
Eric Warren was stepping down from his position as Chief Commercial Officer of the Company, effective as of April 18, 2025.
Departed

Antonio M. Gotto, Jr., M.D., D.Phil.

Director
ESPR · Esperion Therapeutics, Inc.
Effective
2025-06-01
Filed
April 1, 2025, 7:59 PM ET
On April 1, 2025, Antonio M. Gotto, Jr., M.D., D. Phil. notified the Board of the Company of his decision to resign from the Board, including his position as a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), effective June 1, 2025.
Departed

Nicole Vitullo

Director
ESPR · Esperion Therapeutics, Inc.
Effective
2025-06-01
Filed
April 1, 2025, 7:59 PM ET
On April 1, 2025, Nicole Vitullo notified the Board of Directors (the “Board”) of Esperion Therapeutics, Inc. (the “Company”) of her decision to resign from the Board, including her positions as a member of the Audit Committee of the Board (the “Audit Committee”) and Compliance Committee of the Board, effective June 1, 2025.
Appointed

Robert E. Hoffman

Director and Chairperson of the Audit Committee
ESPR · Esperion Therapeutics, Inc.
Effective
2025-04-01
Filed
April 1, 2025, 7:59 PM ET
On April 1, 2025, upon the recommendation of the Nominating and Corporate Governance Committee, the Board elected Robert E. Hoffman to the Board, effective April 1, 2025.

Earnings & guidance

2025-FY EPS reported -$0.11 filing →

Materiality & sentiment trend

Max materiality 1.00 · Median 0.72 · Most common event other_material

26 positive 3 negative 21 neutral

source · ESPR on sec.gov